Oncology · Medical Literature
[Comment] Intravesical pirarubicin after nephroureterectomy
Abstract
Randomised trials in rare cancers are scarce, and those that achieve adequate enrolment and methodological rigour warrant recognition. Upper tract urothelial carcinoma, which comprises only 5–10% of urothelial malignancies, presents unique challenges for trialists because of its low incidence and heterogeneous presentation. Despite its rarity, however, upper tract urothelial carcinoma carries a disproportionately high risk of bladder recurrence after radical nephroureterectomy, affecting 22–47% of patients in contemporary series.
Clinical relevance
Does a single, early intravesical instillation of pirarubicin (30 mg) administered within 24 hours of radical nephroureterectomy reduce bladder recurrence compared with observation alone in patients with upper tract urothelial carcinoma (stage 0a–III)? __SNAPSHOT__ {"studyDesign":"Multicentre, open-label, randomised, phase 3 superiority trial (JCOG1403) with a two-stage registration design; the submitted abstract is an invited commentary by Leow and Chang contextualising this trial","setting":"44 academic and oncology centres in Japan; Urologic Oncology Study Group of the Japan Clinical Oncology Group","sampleSize":"n=304 randomised (pirarubicin: n=153; observation: n=151); 352 enrolled at first (pre-surgical) registration, 348 underwent radical nephroureterectomy","population":"Adults aged 20–80 years with previously untreated, clinical stage 0a–III upper tract urothelial carcinoma, ECOG performance status 0–1, no history or current cystoscopic evidence of bladder cancer; 74% male, 26% female","intervention":"Single intravesical instillation of pirarubicin 30 mg in 30 mL, administered within 24 hours of radical nephroureterectomy and retained in the bladder for 30 minutes; patients with pT3/T4 or pN+ disease received adjuvant gemcitabine–cisplatin chemotherapy","comparator":"Observation without intravesical instillation (current standard of care); patients with pT3/T4 or pN+ disease also received adjuvant gemcitabine–cisplatin","primaryOutcome":"Relapse-free survival (RFS), analysed in the intention-to-treat population (all second-registration patients); secondary endpoints included overall survival (OS), intravesical RFS (IVRFS), non-intravesical RFS, and adverse events","followUp":"Median 4.3 years (IQR 3.4–5.1)","fundingSource":"Government/non-profit: Japan Agency for Medical Research and Development and National Cancer Centre Research and Development Fund, Japan"}
Key findings
The primary endpoint was met. Three-year relapse-free survival was 60.0% (95% CI 51.7–67.3) in the pirarubicin group versus 47.0% (95% CI 38.7–54.9) in the observation group (HR 0.67, 90.96% CI 0.50–0.88; p=0.0066), representing an absolute improvement of approximately 13 percentage points at 3 years (calculated). No statistically significant improvement was observed in non-intravesical relapse-free survival or overall survival, indicating that the benefit was driven primarily by reduction in bladder recurrence rather than systemic disease control. The safety profile was characterised as manageable; grade 3 haematuria occurred in a small proportion of patients in the pirarubicin group (exact incidence not reported in the available abstract/commentary). The primary analysis was performed after 153 events, which was fewer than the 166 events pre-specified in the original sample size calculation; however, this timing had been prospectively defined and the treatment effect remained statistically significant across sensitivity analyses. NNT at 3 years: approximately 8 (calculated from absolute risk difference of ~13%).
Practice implications
IMPORTANT LIMITATION: The abstract submitted for this summary is an invited editorial commentary (Leow & Chang), not the primary trial report. All quantitative data cited here derive from the primary JCOG1403 trial (Ito et al., Lancet Oncology, July 10, 2026, same issue), as identified through indexed sources; clinicians should consult the primary publication for complete data. JCOG1403 provides the first phase 3 randomised evidence that a single, early postoperative intravesical instillation of pirarubicin significantly reduces relapse-free survival events (principally through bladder recurrence reduction) in patients undergoing radical nephroureterectomy for UTUC stages 0a–III. The intervention did NOT demonstrate significant benefit in non-intravesical RFS or overall survival, meaning the procedure does not appear to alter systemic disease biology or mortality, only intravesical recurrence risk. Findings apply specifically to ECOG PS 0–1 Japanese patients without prior or concurrent bladder cancer; generalisability to non-Japanese ethnic populations, those with concurrent bladder carcinoma history, or those with higher performance status is uncertain. Pirarubicin's superiority over other intravesical agents (e.g., mitomycin C) was not tested in this trial; agent selection cannot be ranked against alternatives based on this study alone. Given the established bladder recurrence rate of 22–47% after nephroureterectomy, the statistically significant and clinically meaningful 13-percentage-point absolute improvement in 3-year RFS (NNT ~8, calculated) strengthens the case for routine adoption, but should be contextualised within each patient's surgical risk for immediate postoperative intravesical instillation and local drug availability. __LIMITATIONS__ Open-label design introduces performance and detection bias, particularly for surveillance cystoscopy frequency and reporting of recurrence.,Exclusively Japanese patient population limits ethnic and geographic generalisability.,Primary analysis was triggered at 153 events rather than the pre-planned 166 events, slightly underpowering the pre-specified design, though prospectively defined and sensitivity analyses remained significant.,Preoperative ureteroscopy was performed in only 37% of participants, and 8 randomised patients were found not to have urothelial carcinoma on final pathology, introducing a degree of inclusion imprecision.,No significant improvement in overall survival or non-intravesical RFS; the benefit is confined to bladder recurrence reduction, a surrogate endpoint rather than a mortality endpoint.,No head-to-head comparison with mitomycin C or other intravesical agents; clinicians cannot determine agent superiority from this trial.,Patients with prior bladder cancer were excluded, limiting applicability in a clinically common comorbid group.,Pirarubicin is not approved or widely available in all countries, creating barriers to global implementation.,Grade 3 haematuria, while described as occurring in a small proportion, was not quantified in the available abstract, precluding full safety assessment.,Adjuvant systemic chemotherapy co-administered to high-risk (pT3/T4, pN+) patients in both arms may confound subgroup interpretation. __BOTTOM_LINE_CATEGORY__ practice_changing __BOTTOM_LINE__ JCOG1403 provides the first phase 3 RCT evidence that a single intravesical instillation of pirarubicin 30 mg within 24 hours of radical nephroureterectomy significantly improves 3-year relapse-free survival (60.0% vs. 47.0%; HR 0.67; p=0.0066), driven by reduction in bladder recurrence, with a manageable adverse event profile. This supports adoption of early postoperative intravesical chemotherapy as standard of care following nephroureterectomy for UTUC, consistent with existing EAU, NCCN, and AUA guideline recommendations, though clinicians should note the absence of OS benefit and the exclusively Japanese study population. Where pirarubicin is unavailable, extrapolation to mitomycin C (supported by the ODMIT-C trial) is reasonable pending head-to-head comparative data.